Open access
Aug 2026
Selection of effective LRAs using a newly designed in vitro HIV latency reactivation protocol: toward future application in HIV samples
A simple and reproducible assay to identify compounds capable of reactivating latent virus, a key step in cure strategies, is developed and validated and identified Tandutinib, a tyrosine kinase and mTOR inhibitor, as a novel LRA candidate with appreciable latency-reversing activity in the ACH2 model.
A. Neri, Arianna Rotili, Elena Morrocchi et al.
· Microbiology spectrum · 0 citations